Specialty Pharmaceuticals & Trade Director

Glaukos Corporation is dedicated to pioneering innovative treatments for chronic eye diseases, focusing primarily on glaucoma, corneal disorders, and retinal diseases. Founded in 1998 and headquartered in Aliso Viejo, California, Glaukos is at the forefront of transforming the ophthalmic market through the development of novel therapies that advance existing standards of care for patients worldwide.

One of the significant breakthroughs by Glaukos is the introduction of Micro-Invasive Glaucoma Surgery (MIGS), providing an excellent alternative to traditional glaucoma treatments. Since launching its first MIGS device in 2012, Glaukos has taken remarkable strides in enhancing patient outcomes and offering cutting-edge solutions to healthcare professionals. With a commitment to innovation, the company invests approximately 30% of its annual sales back into research and development, ensuring a constant pipeline of advanced therapies designed to address the evolving needs in ophthalmology.